Flubendazole

Catalog No.S1837 Batch:S183702

Print

Technical Data

Formula

C16H12FN3O3
Molecular Weight 313.28 CAS No. 31430-15-6
Solubility (25°C)* In vitro DMSO 15 mg/mL (47.88 mM)
Water Insoluble
Ethanol Insoluble
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Flubendazole (Flumoxanal, NSC 313680) is an autophagy inducer by targeting Atg4B, used to treat internal parasite and worm infection.
Targets
Atg4B [7]
In vitro Flubendazole results in morphological changes included contraction of the soma region, formation of blebs on the tegument, rostellar disorganization, loss of hooks and destruction of microtriches in Echinococcus granulosus. [1] Flubendazole have a bicyclic ring system in which a benzene has been fused to the -4 and -5 positions of the heterocycle (imidazole). [2] Flubendazole and Albendazole shows similar potency in affecting rat embryonic development in vitro, inducing retardation of growth and dysmorphogenic effects at concentrations ≥0.5 μg/mL. [3]
In vivo Flubendazole (6.32 mg/kg/day) initially induces an arrest of embryonic development followed by a generalized cell death that leads to 100% embryolethality by gestation day (GD) 12.5. Flubendazole (3.46 mg/kg/day) markedly reduces embryonic development by GD 12.5 without causing cell death. [4] Flubendazole in olive oil causes a statistically significant increase in embryolethality at doses of 7.83 mg/kg per day and higher, with complete resorption in all dams at 31.33 mg/kg per day in rats. [5] Flubendazole treatment causes a slight increase of metyrapone and daunorubicin activities in hepatic as well as intestinal cytosol in birds. Flubendazole treatment leads to statistically significant inhibition of intestinal GST activity. Flubendazole treatment leads to slight but significant inhibition (decrease to 69%) of 7-ethoxyresorufin activity in hepatic microsomes. [6]

Protocol (from reference)

Customer Product Validation

Data from [Data independently produced by , , RSC Adv, 2018, 8:5286-5297]

Selleck's Flubendazole has been cited by 3 publications

Proteomic analysis of the urothelial cancer landscape [ Nat Commun, 2024, 15(1):4513] PubMed: 38802361
Mebendazole is unique among tubulin-active drugs in activating the MEK-ERK pathway [ Sci Rep, 2020, 10(1):13124] PubMed: 32753665
Discovery of VEGFR2 inhibitors by integrating naïve Bayesian classification, molecular docking and drug screening approaches [De Kang, et al. RSC Advances, 2018, 10.1039/C7RA12259D]

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.